Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Manhattan Hematology Oncology Associates, New York

Inova Schar Cancer Institute, Fairfax

University of Virginia School of Medicine, Charlottesville

Mayo Clinic - Jacksonville, Jacksonville

Memorial Hospital West, Pembroke Pines

West Cancer Center - East Campus, Germantown

University Hospitals Cleveland Medical Center, Cleveland

Gabrail Cancer and Research Center, Canton

Trihealth Kenwood, Cincinnati

Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion, Grand Rapids

Mayo Clinic - Rochester, Rochester

Washington University School of Medicine Center for Advanced Medicine, St Louis

Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha

University of Texas MD Anderson Cancer Center, Houston

Utah Cancer Specialists, Salt Lake City

Mayo Clinic in Arizona - Phoenix Campus, Phoenix

San Juan Oncology Associates, Farmington

Norris Comprehensive Cancer Center, Los Angeles

UCLA Health - Santa Monica Parkside Cancer Care, Santa Monica

Torrance Memorial Physician Network - Cancer Care and Infusion Center, Torrance

PIH Health, Whittier

Cancer and Blood Specialty Clinic, Los Alamitos

Pacific Cancer Medical Center, Anaheim

UCI Health - Chao Family Comprehensive Cancer Center, Orange

Comprehensive Blood and Cancer Center - Bakersfield, Bakersfield

Central Arkansas Radiation Therapy Institute - Cancer Center, Little Rock

Englewood Health, Englewood